CeriBell, Inc (CBLL) fair value analysis
Nasdaq · Updated 2026-10-19
CBLL price how computed
Valuation status
No fair-value estimate yetCBLL has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for CBLL yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $25.04
- Sector
- Healthcare
- 12-month range
- $10.92–$27.64
- Market cap
- $961M
- From 52-week high
- -9.4%
- Shares outstanding
- 38.4M
- Rank in Healthcare by quality score
- #97 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
I don't have reliable information about a company with the ticker symbol CBLL on Nasdaq in the Healthcare sector. Rather than provide potentially inaccurate information about what this company does or where it operates, I must decline to write the requested sentences. If you could verify the correct ticker symbol or provide additional details about the company, I would be happy to help.
CBLL currently ranks #97 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $961M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $102M
- Net margin
- -64.7%
- EPS (TTM)
- $-1.62
- Gross margin
- 92.3%
- Debt / equity
- 0.17
- Revenue growth (3-yr avg)
- 47.3%
- Shares outstanding
- 38.4M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Expanding
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 50 · neutral
- 50-day average
- $24.03
- 200-day average
- $20.54
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 5 beat, 3 missed
- Quarter by quarter
- 2026-06 ▼ miss (-13.3%)
2026-03 ▲ beat (+2.6%)
2025-12 ▲ beat (+12.2%)
2025-09 ▲ beat (+9.8%)
2025-06 ▲ beat (+5.0%)
2025-03 ▲ beat (+21.7%)
2024-12 ▼ miss (-27.5%)
2024-09 ▼ miss (-112.6%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 8 buy · 0 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $28.6
- Target vs last price
- +14.2%
What our data shows for CBLL
- Shares are trading in the upper third of their 12-month price range of $10.92–$27.64.
- The 14-day relative strength index sits at a neutral 50.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- CBLL's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the CBLL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is CBLL stock undervalued?
TickrTrends has no fair-value estimate for CBLL yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is CBLL's TickrTrends verdict?
CBLL is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does CBLL compare to other Healthcare stocks?
CBLL ranks #97 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is CBLL overbought or oversold?
CBLL's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does CBLL report earnings next?
CBLL's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does CBLL usually beat earnings estimates?
Over its last 8 reported quarters CBLL beat the consensus estimate 5 times and missed 3 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about CBLL?
Of 8 analysts covering CBLL, 8 rate it a buy, 0 a hold and 0 a sell - buy-leaning, with a consensus price target of $28.6 (+14.2% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.